# Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis

> **NCT06183242** · PHASE2,PHASE3 · COMPLETED · sponsor: **POLYSAN Scientific & Technological Pharmaceutical Company** · enrollment: 328 (actual)

## Conditions studied

- Cholestasis, Intrahepatic

## Interventions

- **DRUG:** Remaxa, enteric-coated tablets
- **DRUG:** Remaxol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06183242
- **Lead sponsor:** POLYSAN Scientific & Technological Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-27
- **Primary completion:** 2024-09-24
- **Final completion:** 2024-10-10
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06183242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06183242, "Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06183242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*